Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has ...

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say ...

In the first arrangement of its kind, Eli Lilly to connect patients through telemedicine to providers of Alzheimer’s drugs.

Eli Lilly's direct-to-consumer platform LillyDirect has been expanded to include in-person and telehealth services for people ...

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...

LillyDirect will help provide services to millions of patients who have yet to be formally diagnosed with the disease.

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

The platform features Healthgrades, a tool intended to connect Alzheimer's patients to experienced local clinicians.

The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...